DeepCyte Raises $1.5M to Bring Single-Cell AI Toxicology to Drug Development

Contributed by: PR Newswire

Tags

DeepCyte-AI-Toxicolog

More Like This

PR Newswire associated0

ThinkCyte expands product portfolio to drive innovation in drug discovery and disease research.

ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

PR Newswire associated0

Cellply launches its end-to-end single cell potency characterization platform VivaCyte

Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

Mytos Co-Founders: Ali Afshar, Ph.D (left), CEO and Ignacio Willats (right). Photo credit: Mytos

Mytos Announces $19M Series A Funding to Automate Human Cell Manufacturing and Further Accelerate Growth

ThinkCyte Secures $32 million in Series C Funding to Drive Global Expansion of VisionSort™

PR Newswire associated0

InSphero and FDA's NCTR Publish the Largest Benchmarking Study Demonstrating Early Detection of Liver Toxicity Using 3D Liver Microtissues

Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients